Spruce Biosciences (SPRB) Operating Expenses (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Operating Expenses of $12.0 million for Q1 2026, down 17.29% year-over-year from $14.5 million in Q1 2025, and up 7.99% quarter-over-quarter from $11.1 million in Q4 2025.
Spruce Biosciences (SPRB) Operating Expenses (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Operating Expenses for 8 consecutive years, with $12.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 17.29% year-over-year to $12.0 million; the TTM figure through Mar 2026 stood at $34.0 million (down 44.18% YoY), while the FY2025 annual figure was $36.5 million, down 40.2% from the prior year.
- Operating Expenses grew to $12.0 million in Q1 2026 per SPRB's latest filing, from $11.1 million in the prior quarter.
- Across five years, Operating Expenses topped out at $24.8 million in Q4 2024 and bottomed at $2.7 million in Q2 2025.
- Historically, Operating Expenses has averaged $12.9 million across 5 years, with a median of $12.0 million in 2026.
- Annual changes were most pronounced in 2024 — Operating Expenses jumped 76.29% — and 2025, when it sank 76.88%.
- Spruce Biosciences' Operating Expenses stood at $12.1 million in 2022, then rose by 16.03% to $14.1 million in 2023, then surged by 76.29% to $24.8 million in 2024, then slumped by 55.19% to $11.1 million in 2025, then grew by 7.99% to $12.0 million in 2026.
- Business Quant data shows SPRB's Operating Expenses at $12.0 million in Q1 2026, $11.1 million in Q4 2025, and $8.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Spruce Biosciences | 127.07 Mn | 127.07 Mn | - | 16.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.51 Mn |
| Mar 31, 2026 | 11.99 Mn |
| Dec 31, 2025 | 11.10 Mn |
| Sep 30, 2025 | 8.23 Mn |
| Jun 30, 2025 | 2.69 Mn |
| Mar 31, 2025 | 14.49 Mn |
| Dec 31, 2024 | 24.77 Mn |
| Sep 30, 2024 | 10.01 Mn |
| Jun 30, 2024 | 11.65 Mn |
| Mar 31, 2024 | 14.64 Mn |
| Dec 31, 2023 | 14.05 Mn |
| Sep 30, 2023 | 16.73 Mn |
| Jun 30, 2023 | 16.14 Mn |
| Mar 31, 2023 | 15.16 Mn |
| Dec 31, 2022 | 12.11 Mn |
| Sep 30, 2022 | 11.56 Mn |
| Jun 30, 2022 | 11.88 Mn |
| Mar 31, 2022 | 11.73 Mn |
| Dec 31, 2021 | 9.14 Mn |
| Sep 30, 2021 | 11.40 Mn |